ZA200905159B - Combination of LBH589 with other therapeutic agents for treating cancer - Google Patents

Combination of LBH589 with other therapeutic agents for treating cancer

Info

Publication number: ZA200905159B
Authority: ZA; South Africa
Prior art keywords: lbh589; combination; therapeutic agents; treating cancer; cancer
Prior art date: 2007-02-15

Application number

ZA200905159A

Other languages

English (en)

Inventor

Peter Wisdom Atadja

Wenlin Shao

Kapil N Bhalla

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-15

Filing date

2009-07-23

Publication date

2010-05-26

2009-07-23 Application filed by Novartis Ag filed Critical Novartis Ag

2010-05-26 Publication of ZA200905159B publication Critical patent/ZA200905159B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Hematology (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200905159A 2007-02-15 2009-07-23 Combination of LBH589 with other therapeutic agents for treating cancer ZA200905159B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US89000507P	2007-02-15	2007-02-15

Publications (1)

Publication Number	Publication Date
ZA200905159B true ZA200905159B (en)	2010-05-26

Family

ID=39560929

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200905159A ZA200905159B (en)	2007-02-15	2009-07-23	Combination of LBH589 with other therapeutic agents for treating cancer

Country Status (21)

Country	Link
US (7)	US20100069458A1 (xx)
EP (3)	EP2491923A3 (xx)
JP (1)	JP2010519209A (xx)
KR (1)	KR20090110913A (xx)
CN (1)	CN101626758A (xx)
AR (1)	AR065335A1 (xx)
AU (1)	AU2008216327A1 (xx)
BR (1)	BRPI0807812A2 (xx)
CA (1)	CA2677651A1 (xx)
CL (1)	CL2008000470A1 (xx)
CO (1)	CO6220928A2 (xx)
EC (1)	ECSP099576A (xx)
IL (1)	IL200193A0 (xx)
MA (1)	MA31205B1 (xx)
MX (1)	MX2009008584A (xx)
PE (1)	PE20090519A1 (xx)
RU (1)	RU2009134223A (xx)
TN (1)	TN2009000344A1 (xx)
TW (1)	TW200848022A (xx)
WO (1)	WO2008100985A2 (xx)
ZA (1)	ZA200905159B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080051380A1 (en)	2006-08-25	2008-02-28	Auerbach Alan H	Methods and compositions for treating cancer
EP2117598A2 (en) *	2007-01-10	2009-11-18	Novartis AG	Formulations of deacetylase inhibitors
JP2010520176A (ja)	2007-03-01	2010-06-10	ノバルティスアーゲー	５−（２，４−ジヒドロキシ−５−イソプロピル−フェニル）−４−（４−モルホリン−４−イルメチル−フェニル）−イソオキサゾール−３−カルボン酸エチルアミドの酸付加塩、水和物および多形、ならびにこれらの形態を含む製剤
CL2008002786A1 (es) *	2007-09-20	2009-05-15	Novartis Ag	Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.
ME02230B (me)	2009-01-08	2016-02-20	Curis Inc	Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
JO3002B1 (ar)	2009-08-28	2016-09-05	Irm Llc	مركبات و تركيبات كمثبطات كيناز بروتين
US8491927B2 (en)	2009-12-02	2013-07-23	Nimble Epitech, Llc	Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP2557923A4 (en) *	2010-04-16	2013-10-23	Curis Inc	TREATMENT OF CANCER DISORDERS WITH K-RAS MUTATIONS
CN102241628B (zh) *	2010-05-14	2015-11-25	中国人民解放军总医院	(2e)-3-苯基-n-[2,2,2-三氯-1-[[(8-喹啉基氨基)硫代甲基]氨基]乙基]-2-丙烯酰胺及其医药用途
NZ604040A (en)	2010-06-03	2015-02-27	Pharmacyclics Inc	The use of inhibitors of bruton’s tyrosine kinase (btk)
RU2013114246A (ru) *	2010-09-01	2014-10-20	Новартис Аг	Комбинация hdac ингибиторов с лекарственными средствами против тромбоцитопении
PE20141382A1 (es)	2011-04-01	2014-11-04	Curis Inc	Inhibidor de la fosfoinositida-3-quinasa con un grupo de union a zinc
WO2012149493A2 (en) *	2011-04-28	2012-11-01	Sloan-Kettering Institute For Cancer Research	Hsp90 combination therapy
NZ618367A (en) *	2011-06-14	2016-01-29	Novartis Ag	Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
US20130178483A1 (en) *	2011-06-28	2013-07-11	Pharmacyclics, Inc.	Methods and Compositions for Inhibition of Bone Resorption
CA2863679A1 (en)	2011-08-17	2014-05-30	Dennis Brown	Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
CN102949722A (zh) *	2011-08-26	2013-03-06	中国医学科学院放射医学研究所	基于p38抑制剂和细胞生长因子的新颖药物组合物
WO2013070996A1 (en)	2011-11-11	2013-05-16	Novartis Ag	Method of treating a proliferative disease
US20150087687A1 (en)	2012-03-23	2015-03-26	Dennis Brown	Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
AU2013280644B2 (en)	2012-06-26	2018-08-02	Jeffrey A. BACHA	Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
KR20150032340A (ko)	2012-07-24	2015-03-25	파마시클릭스, 인코포레이티드	브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
US10106778B2 (en)	2012-11-08	2018-10-23	Whitehead Institute For Biomedical Research	Selective targeting of cancer stem cells
JP2016512549A (ja) *	2013-03-14	2016-04-28	ファーマサイクリックスエルエルシー	ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
JP2016519684A (ja)	2013-04-08	2016-07-07	デニスエムブラウン	準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
JP2017509336A (ja)	2014-03-20	2017-04-06	ファーマサイクリックスエルエルシー	ホスホリパーゼｃガンマ２及び耐性に関連した変異
US10398672B2 (en)	2014-04-29	2019-09-03	Whitehead Institute For Biomedical Research	Methods and compositions for targeting cancer stem cells
KR20160145833A (ko) *	2014-05-02	2016-12-20	온코에틱스 게엠베하	티에노트리아졸로디아제핀 화합물을 사용한 급성 골수성 백혈병 및/또는 급성 림프아구성 백혈병의 치료 방법
TWI735413B (zh) *	2014-06-02	2021-08-11	國立陽明交通大學	抗藥性癌症之治療方法
EP3154952A4 (en) *	2014-06-10	2018-03-14	University of South Carolina	Methods and compositions for treatment of her-positive cancers
MA41544A (fr) *	2015-02-19	2017-12-26	Novartis Ag	Dosages de panobinostat pour le traitement du myélome multiple
WO2018023017A1 (en)	2016-07-29	2018-02-01	Janssen Pharmaceutica Nv	Methods of treating prostate cancer
KR101941045B1 (ko) *	2017-08-09	2019-01-22	연세대학교 산학협력단	암의 예방 또는 치료용 약학적 조성물
KR101988124B1 (ko) *	2017-08-31	2019-06-11	사회복지법인 삼성생명공익재단	암 연관 섬유아세포 표적용 약학적 조성물
PE20211050A1 (es)	2018-08-10	2021-06-04	Navire Pharma Inc	Inhibidores de ptpn11
CA3112177A1 (en)	2018-09-11	2020-03-19	Curis, Inc.	Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN115137716A (zh) *	2021-04-19	2022-10-04	海军军医大学第一附属医院第二军医大学第一附属医院上海长海医院	紫草素及其药学上可接受的盐类在制备预防或治疗绝经后骨质疏松症药物中的应用
CN118615291A (zh) *	2024-04-19	2024-09-10	三峡大学	角鲨烯环氧酶新型抑制剂及其在制备治疗抗乳腺癌的药物上的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1524747A (en)	1976-05-11	1978-09-13	Ici Ltd	Polypeptide
LU88769I2 (fr)	1982-07-23	1996-11-05	Zeneca Ltd	Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en)	1983-10-12	1983-11-16	Ici Plc	Steroid derivatives
US5093330A (en)	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en)	1989-08-11	1991-04-23	Harbor Branch Oceanographic Institution, Inc.	Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en)	1990-05-07	1995-03-07	Ciba-Geigy Corporation	Hydrazones
NZ243082A (en)	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en)	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
TW225528B (xx)	1992-04-03	1994-06-21	Ciba Geigy Ag
EP1238986B1 (en)	1992-10-28	2008-06-25	Genentech, Inc.	Use of Vascular endothelial cell growth factor antagonists
GB9314893D0 (en)	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
DE69536015D1 (de)	1995-03-30	2009-12-10	Pfizer Prod Inc	Chinazolinone Derivate
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en)	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
DK0836605T3 (da)	1995-07-06	2002-05-13	Novartis Ag	Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5760041A (en)	1996-02-05	1998-06-02	American Cyanamid Company	4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
SK284073B6 (sk)	1996-04-12	2004-09-08	Warner-Lambert Company	Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
WO1997049688A1 (en)	1996-06-24	1997-12-31	Pfizer Inc.	Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NZ334821A (en)	1996-08-30	2000-12-22	Novartis Ag	Method for producing epothilones
DE69724269T2 (de)	1996-09-06	2004-06-09	Obducat Ab	Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de)	1996-09-11	2001-05-10	Schering Ag	Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en)	1996-09-13	1998-03-19	Gerald Mcmahon	Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en)	1996-10-17	1998-04-22	Pfizer Inc.	4-Aminoquinazoline derivatives
CN100344627C (zh)	1996-11-18	2007-10-24	生物技术研究有限公司(Gbf)	埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
CO4950519A1 (es)	1997-02-13	2000-09-01	Novartis Ag	Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es)	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en)	1997-10-03	1997-12-03	Pharmacia & Upjohn Spa	Polymeric derivatives of camptothecin
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
ATE307123T1 (de)	1998-02-25	2005-11-15	Sloan Kettering Inst Cancer	Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
EP1107964B8 (en)	1998-08-11	2010-04-07	Novartis AG	Isoquinoline derivatives with angiogenesis inhibiting activity
UA71587C2 (uk)	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en)	1998-11-10	1999-01-06	Novartis Ag	Organic compounds
EP1135470A2 (en)	1998-11-20	2001-09-26	Kosan Biosciences, Inc.	Recombinant methods and materials for producing epothilone and epothilone derivatives
EP2016953A3 (en)	1998-12-22	2009-04-15	Genentech, Inc.	Vascular endothelial cell growth factor antagonists and uses thereof
EP1165085B1 (en)	1999-03-30	2006-06-14	Novartis AG	Phthalazine derivatives for treating inflammatory diseases
PE20020354A1 (es)	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR035885A1 (es)	2001-05-14	2004-07-21	Novartis Ag	Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en)	2001-08-07	2001-10-03	Novartis Ag	Organic compounds
RU2311200C2 (ru) *	2001-11-06	2007-11-27	Новартис Аг	Комбинация ингибитора циклооксигеназы-2 и ингибитора гистондезацетилазы
CN1791396A (zh) *	2003-05-21	2006-06-21	诺瓦提斯公司	组蛋白脱乙酰基酶抑制剂与化疗剂的组合
EP1667720A1 (en) *	2003-09-18	2006-06-14	Novartis AG	Combination of a histone deacetylase inhibitor with a death receptor ligand
EP1743654A1 (en) *	2005-07-15	2007-01-17	TopoTarget Germany AG	Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
BRPI0614090A2 (pt) *	2005-08-03	2011-03-09	Novartis Ag	uso de inibidores da hdac para o tratamento do mieloma

2008
- 2008-02-13 EP EP12150317A patent/EP2491923A3/en not_active Withdrawn
- 2008-02-13 CN CN200880005098A patent/CN101626758A/zh active Pending
- 2008-02-13 AR ARP080100618A patent/AR065335A1/es unknown
- 2008-02-13 MX MX2009008584A patent/MX2009008584A/es not_active Application Discontinuation
- 2008-02-13 AU AU2008216327A patent/AU2008216327A1/en not_active Abandoned
- 2008-02-13 KR KR1020097016980A patent/KR20090110913A/ko not_active Withdrawn
- 2008-02-13 JP JP2009549693A patent/JP2010519209A/ja active Pending
- 2008-02-13 RU RU2009134223/15A patent/RU2009134223A/ru not_active Application Discontinuation
- 2008-02-13 CA CA002677651A patent/CA2677651A1/en not_active Abandoned
- 2008-02-13 WO PCT/US2008/053798 patent/WO2008100985A2/en not_active Ceased
- 2008-02-13 BR BRPI0807812-2A patent/BRPI0807812A2/pt not_active Application Discontinuation
- 2008-02-13 EP EP11157791A patent/EP2359818A1/en not_active Withdrawn
- 2008-02-13 EP EP08729719A patent/EP2120900A2/en not_active Withdrawn
- 2008-02-13 US US12/526,962 patent/US20100069458A1/en not_active Abandoned
- 2008-02-13 PE PE2008000314A patent/PE20090519A1/es not_active Application Discontinuation
- 2008-02-14 TW TW097105218A patent/TW200848022A/zh unknown
- 2008-02-14 CL CL200800470A patent/CL2008000470A1/es unknown
2009
- 2009-07-23 ZA ZA200905159A patent/ZA200905159B/xx unknown
- 2009-07-30 IL IL200193A patent/IL200193A0/en unknown
- 2009-08-13 EC EC2009009576A patent/ECSP099576A/es unknown
- 2009-08-13 CO CO09085032A patent/CO6220928A2/es not_active Application Discontinuation
- 2009-08-14 TN TNP2009000344A patent/TN2009000344A1/fr unknown
- 2009-08-31 MA MA32192A patent/MA31205B1/fr unknown
2012
- 2012-07-25 US US13/557,731 patent/US20130029927A1/en not_active Abandoned
2014
- 2014-12-08 US US14/563,430 patent/US20150094274A1/en not_active Abandoned
2016
- 2016-07-28 US US15/222,370 patent/US20170027909A1/en not_active Abandoned
2017
- 2017-05-17 US US15/597,718 patent/US20170246147A1/en not_active Abandoned
- 2017-11-14 US US15/812,141 patent/US20180071251A1/en not_active Abandoned
2018
- 2018-06-12 US US16/006,137 patent/US20180289670A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2491923A3 (en)	2012-12-26
US20170027909A1 (en)	2017-02-02
MX2009008584A (es)	2009-08-18
EP2120900A2 (en)	2009-11-25
US20130029927A1 (en)	2013-01-31
US20180289670A1 (en)	2018-10-11
US20150094274A1 (en)	2015-04-02
CN101626758A (zh)	2010-01-13
US20170246147A1 (en)	2017-08-31
KR20090110913A (ko)	2009-10-23
TW200848022A (en)	2008-12-16
JP2010519209A (ja)	2010-06-03
CA2677651A1 (en)	2008-08-21
WO2008100985A3 (en)	2008-10-30
EP2359818A1 (en)	2011-08-24
US20180071251A1 (en)	2018-03-15
CL2008000470A1 (es)	2008-08-29
EP2491923A2 (en)	2012-08-29
RU2009134223A (ru)	2011-03-20
ECSP099576A (es)	2009-09-29
TN2009000344A1 (en)	2010-12-31
CO6220928A2 (es)	2010-11-19
AR065335A1 (es)	2009-06-03
MA31205B1 (fr)	2010-02-01
IL200193A0 (en)	2010-04-15
US20100069458A1 (en)	2010-03-18
AU2008216327A1 (en)	2008-08-21
PE20090519A1 (es)	2009-05-29
BRPI0807812A2 (pt)	2020-06-23
WO2008100985A2 (en)	2008-08-21

Publication	Publication Date	Title
ZA200905159B (en)	2010-05-26	Combination of LBH589 with other therapeutic agents for treating cancer
IL248204A0 (en)	2016-11-30	Combined treatment of tumors expressing 38cd
EP2152722A4 (en)	2011-12-28	COMPOSITIONS COMPRISING MIR34 THERAPEUTIC AGENTS FOR TREATING CANCER
IL219992A0 (en)	2012-07-31	Combination therapy for treating cancer and dianostic assays for use therein
ZA201004403B (en)	2012-02-29	Therapeutic cancer treatments
PL2303021T3 (pl)	2019-10-31	Związki do leczenia nowotworu
BRPI0821660A2 (pt)	2015-06-16	Combinações de agentes terapêuticos para tratamento de câncer
IL197315A0 (en)	2009-12-24	Treatment of cancer
IL206563A0 (en)	2010-12-30	Medicament for the treatment of cancer of the pancreas
IL199907A0 (en)	2010-04-15	Composition for treatment of pancreatic cancer
EP2049139A4 (en)	2009-06-24	TREATMENT OF TUMORS EXPRESSING RAS
ZA201003425B (en)	2011-04-28	5-cyano-thienopyridines for the treatment of tumors
EP2144887A4 (en)	2012-10-03	PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
IL199911A0 (en)	2010-04-15	3-cinnolinecarboxamide derivatives and their use for treating cancer
IL210066A0 (en)	2011-02-28	Novel ortho-aminoanilides for the treatment of cancer
IL206189A0 (en)	2010-12-30	Compound for use in the treatment of cancer
GB0707556D0 (en)	2007-05-30	Treatment for cancer
IL226363A0 (en)	2013-06-27	Compounds and methods for treating cancer
EP2056839A4 (en)	2009-09-09	COMBINED APPROACHES FOR THE TREATMENT OF CANCER
HK1138762A (en)	2010-09-03	Combination of lbh589 with other therapeutic agents for treating cancer
IL205339A0 (en)	2010-12-30	Compounds and methods for the treatment of cancer
PT2305654E (pt)	2016-02-04	Agente terapêutico para a dor relacionada com o cancro
GB0600903D0 (en)	2006-02-22	Treatment of cancer
GB0712513D0 (en)	2007-08-08	Treatment of cancer
IL196361A0 (en)	2009-09-22	Combination methods of treating cancer